Applying for CAR-T: The Referral Pathway Step by Step

No one applies for CAR-T on their own. In India the referral is made by your treating haematologist or medical oncologist, almost always after a relapse or after a line of treatment has failed. They send your clinical file to an accredited cell-therapy centre. That centre repeats its own eligibility testing and decides whether to accept the case.

Families often look for an application form, a queue to join, or a hospital desk that takes requests. None of those exist for cell therapy in India. The pathway runs doctor to doctor, and the paperwork travels ahead of the patient. Knowing who holds which decision is what saves weeks.

Where CION sits in this pathway

CION Cancer Clinics does not provide, administer or stock CAR-T or any other cell therapy. The immunotherapy delivered at CION centres is checkpoint-inhibitor and antibody-based day-care treatment, which is a different class of medicine altogether. Our role in the CAR-T pathway is orientation and referral: helping a family work out whether the diagnosis is even in the right category, what a cell-therapy centre will ask for, and what the realistic sequence looks like. Nothing on this page is an offer of a product, a price for one, or a recommendation to use one.

That distinction matters as soon as you start making calls. A hospital that describes itself as a CAR-T partner may hold a referral and billing arrangement rather than a treatment licence. The list of centres that actually collect the cells, give the infusion and hold intensive care in the same building is short, and it is set out in Where Is CAR-T Therapy Available in India?

A centre will not review a case from a summary letter. It needs the histopathology report, flow cytometry or immunohistochemistry documenting CD19, recent imaging, bone-marrow studies, the full sequence of previous treatments with dates, and current blood and organ-function results. Missing CD19 documentation is the commonest reason a file goes back.

Assemble the set once, in one dated folder, and send it complete. Every incomplete file costs a round trip, and a round trip in this pathway is rarely less than a week.

Two habits help more than anything else here. Send the slides and the imaging discs, not only the typed reports, because centres frequently want their own pathologist to look. And keep one dated master set as a single PDF, so it can be forwarded to a second centre without being rebuilt from scratch.

Most of the wait is administrative rather than laboratory time. Referral and record review take days to about two weeks. Eligibility testing at the centre takes roughly a week. Slot allocation and financial clearance are the most variable stage. ImmunoACT describes manufacturing turnaround for NexCAR19 as around eighteen days.

The table below sets the stages out in the order they happen, with what typically stretches each one. It is a shape, not a promise. The only timeline that applies to you is the one quoted by the centre holding your file.

Two things follow from that table. The clock that matters most runs before leukapheresis, and it is the part nobody can compress with money. And disease that is moving quickly does not wait politely for a slot, which is why bridging treatment is planned rather than improvised, and why a delayed referral costs more than a delayed batch.

Nine steps separate a first conversation from an infusion. Your oncologist raises CAR-T, assembles the file and refers. The centre reviews it, tests eligibility and takes the case to a board. A slot and financial clearance follow, then leukapheresis, manufacturing, conditioning chemotherapy, infusion and inpatient monitoring.

1. Your haemato-oncologist raises CAR-T as an option. This normally happens after a relapse, or after a line of treatment has failed, not at diagnosis.
2. The file is assembled. Diagnosis report, CD19 documentation, marrow studies, recent imaging, and the treatment history with dates and responses.
3. The referral goes to an accredited cell-therapy centre. Choose on the product, the diagnosis and the age on the label, not on the hospital brand.
4. The centre reviews the file. It is deciding whether the case even falls inside an approved Indian indication before it spends testing capacity on it.
5. The centre repeats its own eligibility testing. Organ function, cardiac assessment, infection screening, performance status, and confirmation that there is no active central nervous system disease.
6. The case goes to a cell-therapy or tumour board. Ask for the decision and a written, itemised estimate to come out of this step rather than a verbal figure.
7. A slot is allocated and financial clearance is arranged. This is usually where the real waiting happens, because apheresis slots and manufacturing capacity are finite.
8. Leukapheresis, then manufacturing. Cells are collected in a day-care session, moved under cold chain, and prepared over roughly eighteen days for NexCAR19. Bridging treatment may run alongside.
9. Conditioning chemotherapy, infusion and monitoring. Lymphodepletion over a few days, one infusion of about thirty minutes, then admitted monitoring for cytokine release syndrome and neurological toxicity.

A referral being made is not the same as a referral being accepted, and a slot being mentioned is not the same as a slot being held. Have steps four, six and seven confirmed in writing before anyone travels or pays.

Two CD19-directed products hold Indian market authorisation, and they do not cover the same patients. NexCAR19, from ImmunoACT, was approved by the Indian regulator in 2023 from age 15. Qartemi, from Immuneel Therapeutics, was approved and launched in January 2025 for adults with B-cell non-Hodgkin lymphoma.

This matters at referral, not later. The same patient can sit inside one label and outside the other, and the centre you are referred to may administer only one of them.

If the referral is being pointed at the newer product, Qartemi: India’s Second Approved CAR-T Therapy covers what it is and who it is approved for. Where a family is weighing the two, NexCAR19 vs Qartemi: How the Two Indian CAR-T Products Compare sets the labels side by side, and the NexCAR19 eligibility criteria are worked through in detail on their own page.

Centres decline cases, and they decline for clinical reasons: the disease is not CD19-positive, it sits outside the approved indication, organ function will not tolerate lymphodepletion, an infection is active, or central nervous system disease is uncontrolled. Ask for the reason in writing. Asking another centre to review the file is legitimate, but the same reports travel with it.

Where the barrier is age or indication rather than fitness, a different Indian product, an informational look at open clinical trials, or a different line of treatment may be worth discussing with your own oncologist. Where the barrier is fitness, the useful conversation is about what would have to change for the answer to change, and whether that is realistic in the time the disease allows.

What the process costs before treatment even starts

Published reporting in August 2026 put the price of NexCAR19 in India at under ₹30 lakh, described in that coverage as a fraction of CAR-T prices in Western countries, and Qartemi’s launch coverage in January 2025 described it as priced well below global CAR-T. These figures are indicative, as of August 2026, and come from published sources rather than from any rate card of ours.

The product price is never the whole bill. Eligibility testing, repeat imaging, leukapheresis, bridging treatment, lymphodepleting chemotherapy, the admission itself, intensive care if it is needed, supportive medicines such as tocilizumab, and travel and accommodation near the centre are all billed separately. Two centres quoting the same product price can still produce very different final bills, which is why a written, itemised estimate matters more than a headline number. What insurers and schemes have actually settled is set out in Insurance and Scheme Coverage for CAR-T by Product, and the public-sector route in Getting CAR-T at a Government Hospital.

If the next question is where the therapy is physically delivered, Where Is CAR-T Therapy Available in India? explains the difference between a partner hospital and an authorised treatment centre, which is the distinction that most often causes a wasted journey.

If the question is money, start with Qartemi Cost and Access for the newer product, then read Insurance and Scheme Coverage for CAR-T by Product for what has actually been paid.

If the question is still which product fits the diagnosis, read Qartemi: India’s Second Approved CAR-T Therapy alongside NexCAR19 vs Qartemi: How the Two Indian CAR-T Products Compare.

For the wider picture across checkpoint inhibitors, biosimilars and the other classes of immune treatment, start from Immunotherapy Medicines Explained, or from the main immunotherapy section.